AMSTERDAM, The Netherlands, March 28 /PRNewswire/ -- Agendia BV (Amsterdam, The Netherlands) and GeneCare (South Africa) announced today that they have reached an agreement for distribution of MammaPrint(R) and CupPrint(R) in South Africa.
MammaPrint(R), which has been clinically validated, uses a 70-gene profile to classify breast cancer patients as 'low' or 'high' risk of developing distant metastasis in a 10-year period. MammaPrint(R) therefore offers additional information to oncologists and patients concerning the subsequent treatment plan.
The CupPrint(R) test is intended for Cancer of Unknown Primary patients. For these cases finding the primary tumor and therefore providing most appropriate treatment is difficult by conventional techniques; this test identifies the primary tumor reliably which helps the oncologist find the best treatment with the objective of increasing life expectancy and reducing chemotherapy's side effects.
GeneCare is a leading biotechnology company in South Africa that offers a routine diagnostic service based on the development and application of clinically-useful genetic tests with especial focus in early detection and disease prevention.
GeneCare, which combines service with Research & Development, is partner with the Cape Biotech Trust that promotes biotechnology innovation in human health. This partnership positions GeneCare as the first private genetic laboratory in South Africa
Agendia is a world leader in gene expression analysis-based diagnostics. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first to commercialize a diagnostic test - MammaPrint(R) - a prognostic marker to determine the risk assessment of breast cancer recurrence.
Based in Amsterdam, the Netherlands, Agendia is a privately owned biotechnology company that, being a spin off of the Netherlands Cancer Institute, has a strong base in top-level cancer research ensuring access to the latest developments in cancer research. Next to the development of new cancer diagnostics, Agendia offers its expertise in finding new prospective gene expression profiles to companies focusing on new drug development in the area of oncology.
CONTACT: Media contact: Gene Care, Room 202, Christiaan Barnard Annexe,162 Longmarket Str., Cape Town 8000, PO Box 15734, Vlaeberg, 8018, Te;+27-021-422-5538, email@example.com Agendia, Ronald van Klaveren, Tel:+44-7736-377-255, Ronald.firstname.lastname@example.org, Agendia B.V., SlotervaartHospital 9D, Louwesweg 6, 1066EC Amsterdam, The Netherlands